| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | TGF beta 1, 2 and 3 |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| Chemical and physical data | |
| Formula | C6392H9926N1698O2026S44 |
| Molar mass | 144388.22 g·mol−1 |
 N Y (what is this?) (verify) | |
Fresolimumab (GC1008) is ahumanmonoclonal antibody[1] and animmunomodulator. It is intended for the treatment ofidiopathic pulmonary fibrosis (IPF),focal segmental glomerulosclerosis, andcancer[2][3] (kidney cancer andmelanoma).
It binds to and inhibits all isoforms of the proteintransforming growth factor beta (TGF-β).[2]
Fresolimumab was discovered byCambridge Antibody Technology (CAT) scientists[4] and was one of a pair of candidate drugs that were identified for the treatment of the fatal conditionscleroderma. CAT chose to co-develop the two drugsmetelimumab (CAT-192) and fresolimumab withGenzyme. During early development, around 2004, CAT decided to drop development of metelimumab in favour of fresolimumab.[5]
In February 2011Sanofi-Aventis agreed to buy Genzyme for US$20.1 billion.[6]
As of June 2011[update] the drug was being tested in humans (clinical trials) against IPF, renal disease, and cancer.[7][8] On 13 August 2012, Genzyme applied to begin a Phase 2 clinical trial in primary focal segmentalglomerulosclerosis[9] comparing fresolimumab versusplacebo.
As of July 2014[update], Sanofi-Aventis continue to list fresolimumab in their research and development portfolio under Phase II development.[10]
 | Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it. |
 | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |
